Related Experiment Video
Updated: Jun 24, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Blood pressure and heart failure: focused on treatment
Kyeong-Hyeon Chun1, Seok-Min Kang2
1Division of Cardiology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.
Insights
Hypertension significantly contributes to heart failure (HF). Optimal blood pressure (BP) targets for HF patients are unclear, necessitating individualized treatment strategies rather than strict BP goals.
Area of Science:
- Cardiology
- Hypertension Research
Background:
- Hypertension is a primary driver of heart failure (HF), a major global health issue.
- The relationship between hypertension and HF, particularly HF with preserved ejection fraction, is significant.
- Acute hypertensive HF presents challenges, with no specific vasodilator therapy proving universally beneficial.
Purpose of the Study:
- To review the intricate connection between blood pressure (BP) and heart failure (HF).
- To explore the pathophysiology linking BP and HF through existing clinical studies.
- To address the clinical significance and optimal treatment targets for BP in HF patients.
Main Methods:
- Literature review of clinical studies examining the relationship between BP and HF.
- Analysis of pathophysiological mechanisms connecting hypertension and heart failure development.
- Discussion of current treatment strategies and evidence gaps for BP management in HF.
Main Results:
- Hypertension is a key factor in HF development, especially HF with preserved ejection fraction.
- Optimal BP targets for HF patients lack definitive evidence, complicating treatment.
- Current HF medications often lower BP, highlighting BP's importance as a hemodynamic marker.
Conclusions:
- Individualized BP management within tolerable ranges is trending due to guideline gaps.
- Further research is needed to establish concrete BP targets for HF treatment.
- Understanding the BP-HF nexus is crucial for refining therapeutic strategies.
Abstract:
Heart failure (HF) remains a significant global health burden, and hypertension is known to be the primary contributor to its development. Although aggressive hypertension treatment can prevent heart changes in at-risk patients, determining the optimal blood pressure (BP) targets in cases diagnosed with HF is challenging owing to insufficient evidence. Notably, hypertension is more strongly associated with HF with preserved ejection fraction than with HF with reduced ejection fraction. Patients with acute hypertensive HF exhibit sudden symptoms of acute HF, especially those manifested with severely high BP; however, no specific vasodilator therapy has proven beneficial for this type of acute HF. Since the majority of medications used to treat HF contribute to lowering BP, and BP remains one of the most important hemodynamic markers, targeted BP management is very concerned in treatment strategies. However, no concrete guidelines exist, prompting a trend towards optimizing therapies to within tolerable ranges, rather than setting explicit BP goals. This review discusses the connection between BP and HF, explores its pathophysiology through clinical studies, and addresses its clinical significance and treatment targets.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Diuretics
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inotropic Agents
Antihypertensive Drugs: Action of Diuretics

